Safe announces consolidated sales of €1.18 million +31% in Q3 2021
07 Oktober 2021 - 6:14PM
Safe announces consolidated sales of €1.18 million +31% in Q3 2021
Safe announces consolidated sales of
€1.18 million +31% in Q3 2021
- Quarterly direct sales up significantly:
+31%.
- Cumulative sales over 2021: +27%.
- First sales in the United States
- Internal legal reorganization of Safe
Group
|
Éragny-sur-Oise, France, October 7th,
2021 at 5:35 p.m. CET – Safe (FR0013467123 –
ALSAF), a company specialising in the design,
manufacture and marketing of ready-to-use technologies for back
surgery, with a particular focus on the safety of emergency
vertebral fractures, publishes its third quarter consolidated
revenues.
In thousands euros |
Q3 2021(3 months) |
|
Q3 2020(3 months) |
9M 2021 |
|
9M 2020 |
Direct Sales |
506 |
+12% |
450 |
1
318 |
-1% |
1
331 |
Indirect Sales |
248 |
-24% |
325 |
804 |
-31% |
1
173 |
Subcontracting Sales |
420 |
+256% |
118 |
1
221 |
+935% |
118 |
Total Sales |
1 174 |
+31% |
893 |
3 342 |
+27% |
2 622 |
In the third quarter of 2021, sales rose by 31% (compared with the
first quarter of 2020), driven by the gradual recovery in surgeries
and sales of the new Sycamore and Hickory products, and also due to
the inclusion of Safe Medical sales after it was consolidated at
the end of July 2020.
On a perimeter basis, Safe Orthopaedics' sales
were down by only 3% in the third quarter after a first half down
21% compared to 2020, marking a return to growth driven by the
strong increase in direct sales in Germany by 148% (€110k in Q3
2021 vs. €45k in Q3 2020) and in the US (€54k in Q3 vs. €12k in
Q2), where the group has recruited a sales manager and initiated
direct marketing. In France and Germany, the group also recorded
the first sales generated by the new products Sycamore and Hickory
CE marked on May 24 and 27, 2021 associated with very promising
clinical returns that the group will communicate in the coming
quarters. Indirect sales are down, impacted by the white plans in
Asia Pacific and Latin America.
"Safe Group closes the third quarter of 2021
with global sales growth of 31% {excluding IFRS15 impact} compared
to the first quarter of 2020. Although surgical volume has not yet
returned to pre-health crisis levels, Safe Orthopaedics investments
in the strategic markets of France, Germany and the US and the
launch of new technologies are contributing to our growth. Safe
Medical's activity has accelerated sharply since the second quarter
of 2021, and it is now offering new industrial services since the
qualification of its integrated production site, supporting the
Group's future growth," commented Pierre Dumouchel, Chairman and
CEO of Safe Group.
Internal legal reorganization of Safe
Group
Following the acquisition of LCI Medical (now
Safe Medical), it was decided to create a second operating
subsidiary (Safe Orthopaedics SAS, wholly owned by SAFE SA) to
carry out the Group's historical activities. Thus, in the context
of a partial asset contribution transaction relating to a complete
branch of activity, all the assets (including employees) and
liabilities relating to the said historical activities were
transferred on October 1, 2021 to Safe Orthopaedics SAS.
Consequently, SAFE SA will retain only the administrative and
financial activities and the research and innovation
activities.
Cash position
At the end of the third quarter of 2021, Safe's cash position
amounted to €2,523k, compared with €575k at September 30, 2020.
(Unaudited figures)
Next financial publication
Sales for the second half of 2021, on January 13, 2022 (after
the close of trading).
About Safe GroupThe Safe Group
is a French medical technology group that brings together Safe
Orthopaedics, a pioneer in ready-to-use technologies for spinal
pathologies, and Safe Medical (formerly LCI Medical), a
subcontractor of medical devices for orthopaedic surgery. The group
employs approximately 150 people.
Safe Orthopaedics develops and manufactures kits
combining sterile implants and single-use instruments, available at
all times to the surgeon. These technologies are part of a
minimally invasive approach aimed at reducing the risk of
contamination and infection, to the benefit of the patient and with
a positive impact on hospitalisation times and costs. Protected by
18 patent families, SteriSpineTM kits are CE marked and FDA
approved. Safe Orthopaedics is headquartered in the Paris region
(95610 Eragny sur Oise - France) and has subsidiaries in the UK,
Germany, the USA and the Lyon region where the manufacturing
company is located.For more information:
www.SafeOrthopaedics.com
Safe Medical (formerly LCI Medical) produces
implantable medical devices and ready-to-use instruments. It has an
innovation centre and two production sites in France and Tunisia,
offering numerous industrial services: design, industrialisation,
machining, finishing and sterile packaging. Supported by the French
recovery plan in 2020, the company is investing in additive
printing and will be operational in 2022 with this new technology.
For more information: www.safemedical.fr
Contacts
Safe
Orthopaedics
François-Henri Reynaud
Chief Financial and Administrative Officer
Tel: +33 (0)1 34 21 50
00
investors@safeorthopaedics.com
Press RelationsUlysse
CommunicationPierre-Louis Germain / +33 (0)6 64 79
97 61 / plgermain@ulysse-communication.com Bruno
Arabian / +33 (0)6 87 88 47 26 /
barabian@ulysse-communication.com
SAFE (EU:ALSAF)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
SAFE (EU:ALSAF)
Historical Stock Chart
Von Apr 2023 bis Apr 2024